{"id":"spd503-1-mg","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Tremor"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PDE4 inhibition leads to accumulation of cyclic adenosine monophosphate (cAMP) in immune and inflammatory cells, suppressing the release of pro-inflammatory cytokines and chemokines. This mechanism reduces airway inflammation and mucus production, making it suitable for respiratory inflammatory conditions. The selective PDE4 inhibition aims to provide anti-inflammatory benefits with potentially improved tolerability compared to non-selective phosphodiesterase inhibitors.","oneSentence":"SPD503 is a selective phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory mediator production by increasing intracellular cAMP levels.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:35:48.731Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD)"},{"name":"Asthma"}]},"trialDetails":[{"nctId":"NCT04085172","phase":"PHASE4","title":"A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"Shire","startDate":"2019-09-18","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":396},{"nctId":"NCT01500694","phase":"PHASE3","title":"Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe","status":"COMPLETED","sponsor":"Shire","startDate":"2012-03-20","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":215},{"nctId":"NCT00901576","phase":"PHASE1","title":"A Drug Interaction Study of SPD503 and Concerta Administered Alone and In Combination in Normal Healthy Volunteers","status":"COMPLETED","sponsor":"Shire","startDate":"2009-05-18","conditions":"Healthy","enrollment":38},{"nctId":"NCT00367835","phase":"PHASE3","title":"SPD503 (Guanfacine Hydrochloride) in ADHD Plus Oppositional Symptoms","status":"COMPLETED","sponsor":"Shire","startDate":"2006-12-04","conditions":"ADHD","enrollment":217},{"nctId":"NCT01470469","phase":"PHASE2","title":"SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)","status":"COMPLETED","sponsor":"Shire","startDate":"2012-01-04","conditions":"Generalized Anxiety Disorder (GAD), Anxiety, Separation, Phobia, Social","enrollment":83},{"nctId":"NCT00150618","phase":"PHASE3","title":"Safety and Efficacy of SPD503 in Treating ADHD in Children and Adolescents Aged 6-17","status":"COMPLETED","sponsor":"Shire","startDate":"2004-03-30","conditions":"Attention Deficit Disorder With Hyperactivity","enrollment":324},{"nctId":"NCT03662763","phase":"PHASE3","title":"Extended-release Guanfacine Hydrochloride in Children/Adolescents With Attention-deficit/Hyperactivity","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2011-09","conditions":"Attention Deficit Disorder","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Guanfacine hydrochloride"],"phase":"phase_3","status":"active","brandName":"SPD503 (1 mg)","genericName":"SPD503 (1 mg)","companyName":"Shire","companyId":"shire","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SPD503, a medication containing guanfacine hydrochloride, is being studied for its potential to treat ADHD, Attention Deficit Disorder, Generalized Anxiety Disorder, Anxiety, Separation, Phobia, and Social Phobia. It is administered as an extended-release formulation, with clinical trials comparing it to a placebo and extended-release guanfacine hydrochloride.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Intuniv Partial Change Approval","application_number":"Intuniv Partial Change Approval"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}